Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Molecular Brain
Published in: Molecular Brain 1/2013

Open Access 01-12-2013 | Review

Transcriptional regulation and its misregulation in Alzheimer’s disease

Authors: Xiao-Fen Chen, Yun-wu Zhang, Huaxi Xu, Guojun Bu

Published in: Molecular Brain | Issue 1/2013

Login to get access

Abstract

Alzheimer’s disease (AD) is a devastating neurodegenerative disorder characterized by loss of memory and cognitive function. A key neuropathological event in AD is the accumulation of amyloid-β (Aβ) peptide. The production and clearance of Aβ in the brain are regulated by a large group of genes. The expression levels of these genes must be fine-tuned in the brain to keep Aβ at a balanced amount under physiological condition. Misregulation of AD genes has been found to either increase AD risk or accelerate the disease progression. In recent years, important progress has been made in uncovering the regulatory elements and transcriptional factors that guide the expression of these genes. In this review, we describe the mechanisms of transcriptional regulation for the known AD genes and the misregualtion that leads to AD susceptibility.
Literature
1.
Blennow K, de Leon MJ, Zetterberg H: Alzheimer's disease. Lancet. 2006, 368: 387-403. 10.1016/S0140-6736(06)69113-7.PubMedCrossRef
2.
Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002, 297: 353-356. 10.1126/science.1072994.PubMedCrossRef
3.
Cavallucci V, D'Amelio M, Cecconi F: Abeta toxicity in Alzheimer's disease. Mol Neurobiol. 2012, 45: 366-378. 10.1007/s12035-012-8251-3.PubMedCrossRef
4.
5.
Jung CG, Uhm KO, Miura Y, Hosono T, Horike H, Khanna KK, Kim MJ, Michikawa M: Beta-amyloid increases the expression level of ATBF1 responsible for death in cultured cortical neurons. Mol Neurodegener. 2011, 6: 47-10.1186/1750-1326-6-47.PubMedCentralPubMedCrossRef
6.
7.
Ertekin-Taner N: Gene expression endophenotypes: a novel approach for gene discovery in Alzheimer's disease. Mol Neurodegener. 2011, 6: 31-10.1186/1750-1326-6-31.PubMedCentralPubMedCrossRef
8.
Theuns J, Van Broeckhoven C: Transcriptional regulation of Alzheimer's disease genes: implications for susceptibility. Hum Mol Genet. 2000, 9: 2383-2394. 10.1093/hmg/9.16.2383.PubMedCrossRef
9.
10.
Chami L, Checler F: BACE1 is at the crossroad of a toxic vicious cycle involving cellular stress and beta-amyloid production in Alzheimer's disease. Mol Neurodegener. 2012, 7: 52-10.1186/1750-1326-7-52.PubMedCentralPubMedCrossRef
11.
12.
Holsinger RM, McLean CA, Beyreuther K, Masters CL, Evin G: Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. Ann Neurol. 2002, 51: 783-786. 10.1002/ana.10208.PubMedCrossRef
13.
Yang LB, Lindholm K, Yan R, Citron M, Xia W, Yang XL, Beach T, Sue L, Wong P, Price D, et al: Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med. 2003, 9: 3-4. 10.1038/nm0103-3.PubMedCrossRef
14.
Rossner S, Sastre M, Bourne K, Lichtenthaler SF: Transcriptional and translational regulation of BACE1 expression–implications for Alzheimer's disease. Prog Neurobiol. 2006, 79: 95-111. 10.1016/j.pneurobio.2006.06.001.PubMedCrossRef
15.
Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, et al: Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999, 286: 735-741. 10.1126/science.286.5440.735.PubMedCrossRef
16.
Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, Fan W, Kha H, Zhang J, Gong Y, et al: Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci. 2001, 4: 231-232. 10.1038/85059.PubMedCrossRef
17.
Roberds SL, Anderson J, Basi G, Bienkowski MJ, Branstetter DG, Chen KS, Freedman SB, Frigon NL, Games D, Hu K, et al: BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum Mol Genet. 2001, 10: 1317-1324. 10.1093/hmg/10.12.1317.PubMedCrossRef
18.
Kobayashi D, Zeller M, Cole T, Buttini M, McConlogue L, Sinha S, Freedman S, Morris RG, Chen KS: BACE1 gene deletion: impact on behavioral function in a model of Alzheimer's disease. Neurobiol Aging. 2008, 29: 861-873. 10.1016/j.neurobiolaging.2007.01.002.PubMedCrossRef
19.
Laird FM, Cai H, Savonenko AV, Farah MH, He K, Melnikova T, Wen H, Chiang HC, Xu G, Koliatsos VE, et al: BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci. 2005, 25: 11693-11709. 10.1523/JNEUROSCI.2766-05.2005.PubMedCentralPubMedCrossRef
20.
Rajapaksha TW, Eimer WA, Bozza TC, Vassar R: The Alzheimer's beta-secretase enzyme BACE1 is required for accurate axon guidance of olfactory sensory neurons and normal glomerulus formation in the olfactory bulb. Mol Neurodegener. 2011, 6: 88-10.1186/1750-1326-6-88.PubMedCentralPubMedCrossRef
21.
Lange-Dohna C, Zeitschel U, Gaunitz F, Perez-Polo JR, Bigl V, Rossner S: Cloning and expression of the rat BACE1 promoter. J Neurosci Res. 2003, 73: 73-80. 10.1002/jnr.10639.PubMedCrossRef
22.
Kwak YD, Wang R, Li JJ, Zhang YW, Xu H, Liao FF: Differential regulation of BACE1 expression by oxidative and nitrosative signals. Mol Neurodegener. 2011, 6: 17-10.1186/1750-1326-6-17.PubMedCentralPubMedCrossRef
23.
Waby JS, Bingle CD, Corfe BM: Post-translational control of sp-family transcription factors. Curr Genomics. 2008, 9: 301-311. 10.2174/138920208785133244.PubMedCentralPubMedCrossRef
24.
Christensen MA, Zhou W, Qing H, Lehman A, Philipsen S, Song W: Transcriptional regulation of BACE1, the beta-amyloid precursor protein beta-secretase, by Sp1. Mol Cell Biol. 2004, 24: 865-874. 10.1128/MCB.24.2.865-874.2004.PubMedCentralPubMedCrossRef
25.
Letovsky J, Dynan WS: Measurement of the binding of transcription factor Sp1 to a single GC box recognition sequence. Nucleic Acids Res. 1989, 17: 2639-2653. 10.1093/nar/17.7.2639.PubMedCentralPubMedCrossRef
26.
Chu J, Zhuo JM, Pratico D: Transcriptional regulation of beta-secretase-1 by 12/15-lipoxygenase results in enhanced amyloidogenesis and cognitive impairments. Ann Neurol. 2012, 71: 57-67. 10.1002/ana.22625.PubMedCentralPubMedCrossRef
27.
Perkins ND, Edwards NL, Duckett CS, Agranoff AB, Schmid RM, Nabel GJ: A cooperative interaction between NF-kappa B and Sp1 is required for HIV-1 enhancer activation. EMBO J. 1993, 12: 3551-3558.PubMedCentralPubMed
28.
Hirano F, Tanaka H, Hirano Y, Hiramoto M, Handa H, Makino I, Scheidereit C: Functional interference of Sp1 and NF-kappaB through the same DNA binding site. Mol Cell Biol. 1998, 18: 1266-1274.PubMedCentralPubMedCrossRef
29.
Bourne KZ, Ferrari DC, Lange-Dohna C, Rossner S, Wood TG, Perez-Polo JR: Differential regulation of BACE1 promoter activity by nuclear factor-kappaB in neurons and glia upon exposure to beta-amyloid peptides. J Neurosci Res. 2007, 85: 1194-1204. 10.1002/jnr.21252.PubMedCrossRef
30.
Chami L, Buggia-Prevot V, Duplan E, Delprete D, Chami M, Peyron JF, Checler F: Nuclear factor-kappaB regulates betaAPP and beta- and gamma-secretases differently at physiological and supraphysiological Abeta concentrations. J Biol Chem. 2012, 287: 24573-24584. 10.1074/jbc.M111.333054.PubMedCentralPubMedCrossRef
31.
Maxwell P, Salnikow K: HIF-1: an oxygen and metal responsive transcription factor. Cancer Biol Ther. 2004, 3: 29-35. 10.4161/cbt.3.1.547.PubMedCrossRef
32.
Lando D, Peet DJ, Whelan DA, Gorman JJ, Whitelaw ML: Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science. 2002, 295: 858-861. 10.1126/science.1068592.PubMedCrossRef
33.
Sun X, He G, Qing H, Zhou W, Dobie F, Cai F, Staufenbiel M, Huang LE, Song W: Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression. Proc Natl Acad Sci USA. 2006, 103: 18727-18732. 10.1073/pnas.0606298103.PubMedCentralPubMedCrossRef
34.
Zhang X, Zhou K, Wang R, Cui J, Lipton SA, Liao FF, Xu H, Zhang YW: Hypoxia-inducible factor 1alpha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation. J Biol Chem. 2007, 282: 10873-10880. 10.1074/jbc.M608856200.PubMedCrossRef
35.
Guglielmotto M, Aragno M, Autelli R, Giliberto L, Novo E, Colombatto S, Danni O, Parola M, Smith MA, Perry G, et al: The up-regulation of BACE1 mediated by hypoxia and ischemic injury: role of oxidative stress and HIF1alpha. J Neurochem. 2009, 108: 1045-1056. 10.1111/j.1471-4159.2008.05858.x.PubMedCrossRef
36.
Li QY, Wang HM, Wang ZQ, Ma JF, Ding JQ, Chen SD: Salidroside attenuates hypoxia-induced abnormal processing of amyloid precursor protein by decreasing BACE1 expression in SH-SY5Y cells. Neurosci Lett. 2010, 481: 154-158. 10.1016/j.neulet.2010.06.076.PubMedCrossRef
37.
Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, Umesono K, Evans RM: Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA. 1994, 91: 7355-7359. 10.1073/pnas.91.15.7355.PubMedCentralPubMedCrossRef
38.
Tontonoz P, Hu E, Spiegelman BM: Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell. 1994, 79: 1147-1156. 10.1016/0092-8674(94)90006-X.PubMedCrossRef
39.
Mandrekar-Colucci S, Landreth GE: Nuclear receptors as therapeutic targets for Alzheimer's disease. Expert Opin Ther Targets. 2011, 15: 1085-1097. 10.1517/14728222.2011.594043.PubMedCentralPubMedCrossRef
40.
Sastre M, Dewachter I, Rossner S, Bogdanovic N, Rosen E, Borghgraef P, Evert BO, Dumitrescu-Ozimek L, Thal DR, Landreth G, et al: Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci USA. 2006, 103: 443-448. 10.1073/pnas.0503839103.PubMedCentralPubMedCrossRef
41.
McGeer PL, McGeer EG: Inflammation, autotoxicity and Alzheimer disease. Neurobiol Aging. 2001, 22: 799-809. 10.1016/S0197-4580(01)00289-5.PubMedCrossRef
42.
Mahley RW: Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988, 240: 622-630. 10.1126/science.3283935.PubMedCrossRef
43.
Liu CC, Kanekiyo T, Xu H, Bu G: Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013, 9: 106-118. 10.1038/nrneurol.2012.263.PubMedCentralPubMedCrossRef
44.
Herz J, Chen Y: Reelin, lipoprotein receptors and synaptic plasticity. Nat Rev Neurosci. 2006, 7: 850-859. 10.1038/nrn2009.PubMedCrossRef
45.
Chen J, Li Q, Wang J: Topology of human apolipoprotein E3 uniquely regulates its diverse biological functions. Proc Natl Acad Sci USA. 2011, 108: 14813-14818. 10.1073/pnas.1106420108.PubMedCentralPubMedCrossRef
46.
Frieden C, Garai K: Structural differences between apoE3 and apoE4 may be useful in developing therapeutic agents for Alzheimer's disease. Proc Natl Acad Sci U S A. 2012, 109: 8913-8918. 10.1073/pnas.1207022109.PubMedCentralPubMedCrossRef
47.
Zhong N, Weisgraber KH: Understanding the association of apolipoprotein E4 with Alzheimer disease: clues from its structure. J Biol Chem. 2009, 284: 6027-6031.PubMedCentralPubMedCrossRef
48.
Bu G: Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci. 2009, 10: 333-344. 10.1038/nrn2620.PubMedCentralPubMedCrossRef
49.
Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993, 261: 921-923. 10.1126/science.8346443.PubMedCrossRef
50.
Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM: Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer disease meta analysis consortium. JAMA. 1997, 278: 1349-1356. 10.1001/jama.1997.03550160069041.PubMedCrossRef
51.
Laws SM, Hone E, Gandy S, Martins RN: Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription. J Neurochem. 2003, 84: 1215-1236. 10.1046/j.1471-4159.2003.01615.x.PubMedCrossRef
52.
Taddei K, Clarnette R, Gandy SE, Martins RN: Increased plasma apolipoprotein E (apoE) levels in Alzheimer's disease. Neurosci Lett. 1997, 223: 29-32. 10.1016/S0304-3940(97)13394-8.PubMedCrossRef
53.
Lindh M, Blomberg M, Jensen M, Basun H, Lannfelt L, Engvall B, Scharnagel H, Marz W, Wahlund LO, Cowburn RF: Cerebrospinal fluid apolipoprotein E (apoE) levels in Alzheimer's disease patients are increased at follow up and show a correlation with levels of tau protein. Neurosci Lett. 1997, 229: 85-88. 10.1016/S0304-3940(97)00429-1.PubMedCrossRef
54.
Laws SM, Hone E, Taddei K, Harper C, Dean B, McClean C, Masters C, Lautenschlager N, Gandy SE, Martins RN: Variation at the APOE -491 promoter locus is associated with altered brain levels of apolipoprotein E. Mol Psychiatry. 2002, 7: 886-890. 10.1038/sj.mp.4001097.PubMedCrossRef
55.
Pirttila T, Soininen H, Heinonen O, Lehtimaki T, Bogdanovic N, Paljarvi L, Kosunen O, Winblad B, Riekkinen P, Wisniewski HM, Mehta PD: Apolipoprotein E (apoE) levels in brains from Alzheimer disease patients and controls. Brain Res. 1996, 722: 71-77. 10.1016/0006-8993(96)00183-7.PubMedCrossRef
56.
Harr SD, Uint L, Hollister R, Hyman BT, Mendez AJ: Brain expression of apolipoproteins E, J, and A-I in Alzheimer's disease. J Neurochem. 1996, 66: 2429-2435.PubMedCrossRef
57.
Beffert U, Cohn JS, Petit-Turcotte C, Tremblay M, Aumont N, Ramassamy C, Davignon J, Poirier J: Apolipoprotein E and beta-amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are disease-related and apolipoprotein E genotype dependent. Brain Res. 1999, 843: 87-94. 10.1016/S0006-8993(99)01894-6.PubMedCrossRef
58.
Hesse C, Larsson H, Fredman P, Minthon L, Andreasen N, Davidsson P, Blennow K: Measurement of apolipoprotein E (apoE) in cerebrospinal fluid. Neurochem Res. 2000, 25: 511-517. 10.1023/A:1007516210548.PubMedCrossRef
59.
Bien-Ly N, Gillespie AK, Walker D, Yoon SY, Huang Y: Reducing human apolipoprotein E levels attenuates age-dependent Abeta accumulation in mutant human amyloid precursor protein transgenic mice. J Neurosci. 2012, 32: 4803-4811. 10.1523/JNEUROSCI.0033-12.2012.PubMedCentralPubMedCrossRef
60.
Kim J, Jiang H, Park S, Eltorai AE, Stewart FR, Yoon H, Basak JM, Finn MB, Holtzman DM: Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-beta amyloidosis. J Neurosci. 2011, 31: 18007-18012. 10.1523/JNEUROSCI.3773-11.2011.PubMedCentralPubMedCrossRef
61.
Lin-Lee YC, Tanaka Y, Lin CT, Chan L: Effects of an atherogenic diet on apolipoprotein E biosynthesis in the rat. Biochemistry. 1981, 20: 6474-6480. 10.1021/bi00525a028.PubMedCrossRef
62.
Smith JD, Melian A, Leff T, Breslow JL: Expression of the human apolipoprotein E gene is regulated by multiple positive and negative elements. J Biol Chem. 1988, 263: 8300-8308.PubMed
63.
Surguchov AP: The apolipoprotein gene family: organization of upstream elements and regulation of gene expression. Biomed Sci. 1990, 1: 344-353.PubMed
64.
Paik YK, Chang DJ, Reardon CA, Davies GE, Mahley RW, Taylor JM: Nucleotide sequence and structure of the human apolipoprotein E gene. Proc Natl Acad Sci USA. 1985, 82: 3445-3449. 10.1073/pnas.82.10.3445.PubMedCentralPubMedCrossRef
65.
Garcia MA, Vazquez J, Gimenez C, Valdivieso F, Zafra F: Transcription factor AP-2 regulates human apolipoprotein E gene expression in astrocytoma cells. J Neurosci. 1996, 16: 7550-7556.PubMed
66.
Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, et al: ApoE promotes the proteolytic degradation of Abeta. Neuron. 2008, 58: 681-693. 10.1016/j.neuron.2008.04.010.PubMedCentralPubMedCrossRef
67.
Terwel D, Steffensen KR, Verghese PB, Kummer MP, Gustafsson JA, Holtzman DM, Heneka MT: Critical role of astroglial apolipoprotein E and liver X receptor-alpha expression for microglial Abeta phagocytosis. J Neurosci. 2011, 31: 7049-7059. 10.1523/JNEUROSCI.6546-10.2011.PubMedCrossRef
68.
Yue L, Rasouli N, Ranganathan G, Kern PA, Mazzone T: Divergent effects of peroxisome proliferator-activated receptor gamma agonists and tumor necrosis factor alpha on adipocyte ApoE expression. J Biol Chem. 2004, 279: 47626-47632. 10.1074/jbc.M408461200.PubMedCrossRef
69.
Philipp J, Mitchell PJ, Malipiero U, Fontana A: Cell type-specific regulation of expression of transcription factor AP-2 in neuroectodermal cells. Dev Biol. 1994, 165: 602-614. 10.1006/dbio.1994.1279.PubMedCrossRef
70.
Luscher B, Mitchell PJ, Williams T, Tjian R: Regulation of transcription factor AP-2 by the morphogen retinoic acid and by second messengers. Genes Dev. 1989, 3: 1507-1517. 10.1101/gad.3.10.1507.PubMedCrossRef
71.
72.
Damberg M: Transcription factor AP-2 and monoaminergic functions in the central nervous system. J Neural Transm. 2005, 112: 1281-1296. 10.1007/s00702-005-0325-1.PubMedCrossRef
73.
Rossello XS, Igbavboa U, Weisman GA, Sun GY, Wood WG: AP-2beta regulates amyloid beta-protein stimulation of apolipoprotein E transcription in astrocytes. Brain Res. 2012, 1444: 87-95.PubMedCentralPubMedCrossRef
74.
Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, Casali BT, Restivo JL, Goebel WD, James MJ, et al: ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science. 2012, 335: 1503-1506. 10.1126/science.1217697.PubMedCentralPubMedCrossRef
75.
Liang Y, Lin S, Beyer TP, Zhang Y, Wu X, Bales KR, DeMattos RB, May PC, Li SD, Jiang XC, et al: A liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein E expression, secretion and cholesterol homeostasis in astrocytes. J Neurochem. 2004, 88: 623-634. 10.1111/j.1471-4159.2004.02183.x.PubMedCrossRef
76.
Bullido MJ, Valdivieso F: Apolipoprotein E gene promoter polymorphisms in Alzheimer's disease. Microsc Res Tech. 2000, 50: 261-267. 10.1002/1097-0029(20000815)50:4<261::AID-JEMT2>3.0.CO;2-B.PubMedCrossRef
77.
Artiga MJ, Bullido MJ, Frank A, Sastre I, Recuero M, Garcia MA, Lendon CL, Han SW, Morris JC, Vazquez J, et al: Risk for Alzheimer's disease correlates with transcriptional activity of the APOE gene. Hum Mol Genet. 1998, 7: 1887-1892. 10.1093/hmg/7.12.1887.PubMedCrossRef
78.
Bullido MJ, Artiga MJ, Recuero M, Sastre I, Garcia MA, Aldudo J, Lendon C, Han SW, Morris JC, Frank A, et al: A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia. Nat Genet. 1998, 18: 69-71. 10.1038/ng0198-69.PubMedCrossRef
79.
Lambert JC, Pasquier F, Cottel D, Frigard B, Amouyel P, Chartier-Harlin MC: A new polymorphism in the APOE promoter associated with risk of developing Alzheimer's disease. Hum Mol Genet. 1998, 7: 533-540. 10.1093/hmg/7.3.533.PubMedCrossRef
80.
Mui S, Briggs M, Chung H, Wallace RB, Gomez-Isla T, Rebeck GW, Hyman BT: A newly identified polymorphism in the apolipoprotein E enhancer gene region is associated with Alzheimer's disease and strongly with the epsilon 4 allele. Neurology. 1996, 47: 196-201. 10.1212/WNL.47.1.196.PubMedCrossRef
81.
Artiga MJ, Bullido MJ, Sastre I, Recuero M, Garcia MA, Aldudo J, Vazquez J, Valdivieso F: Allelic polymorphisms in the transcriptional regulatory region of apolipoprotein E gene. FEBS Lett. 1998, 421: 105-108. 10.1016/S0014-5793(97)01543-3.PubMedCrossRef
82.
Lambert JC, Berr C, Pasquier F, Delacourte A, Frigard B, Cottel D, Perez-Tur J, Mouroux V, Mohr M, Cecyre D, et al: Pronounced impact of Th1/E47cs mutation compared with -491 AT mutation on neural APOE gene expression and risk of developing Alzheimer's disease. Hum Mol Genet. 1998, 7: 1511-1516. 10.1093/hmg/7.9.1511.PubMedCrossRef
83.
Yoshikai S, Sasaki H, Doh-ura K, Furuya H, Sakaki Y: Genomic organization of the human amyloid beta-protein precursor gene. Gene. 1990, 87: 257-263. 10.1016/0378-1119(90)90310-N.PubMedCrossRef
84.
Goedert M: Neuronal localization of amyloid beta protein precursor mRNA in normal human brain and in Alzheimer's disease. EMBO J. 1987, 6: 3627-3632.PubMedCentralPubMed
85.
Chernak JM: Structural features of the 5' upstream regulatory region of the gene encoding rat amyloid precursor protein. Gene. 1993, 133: 255-260. 10.1016/0378-1119(93)90648-M.PubMedCrossRef
86.
Izumi R, Yamada T, Yoshikai S, Sasaki H, Hattori M, Sakaki Y: Positive and negative regulatory elements for the expression of the Alzheimer's disease amyloid precursor-encoding gene in mouse. Gene. 1992, 112: 189-195. 10.1016/0378-1119(92)90375-Y.PubMedCrossRef
87.
Salbaum JM, Weidemann A, Lemaire HG, Masters CL, Beyreuther K: The promoter of Alzheimer's disease amyloid A4 precursor gene. EMBO J. 1988, 7: 2807-2813.PubMedCentralPubMed
88.
La Fauci G, Lahiri DK, Salton SR, Robakis NK: Characterization of the 5'-end region and the first two exons of the beta-protein precursor gene. Biochem Biophys Res Commun. 1989, 159: 297-304. 10.1016/0006-291X(89)92437-6.PubMedCrossRef
89.
Quitschke WW, Matthews JP, Kraus RJ, Vostrov AA: The initiator element and proximal upstream sequences affect transcriptional activity and start site selection in the amyloid beta-protein precursor promoter. J Biol Chem. 1996, 271: 22231-22239. 10.1074/jbc.271.36.22231.PubMedCrossRef
90.
Quitschke WW, Goldgaber D: The amyloid beta-protein precursor promoter. A region essential for transcriptional activity contains a nuclear factor binding domain. J Biol Chem. 1992, 267: 17362-17368.PubMed
91.
Song W, Lahiri DK: Functional identification of the promoter of the gene encoding the Rhesus monkey beta-amyloid precursor protein. Gene. 1998, 217: 165-176. 10.1016/S0378-1119(98)00340-0.PubMedCrossRef
92.
Pollwein P, Masters CL, Beyreuther K: The expression of the amyloid precursor protein (APP) is regulated by two GC-elements in the promoter. Nucleic Acids Res. 1992, 20: 63-68. 10.1093/nar/20.1.63.PubMedCentralPubMedCrossRef
93.
Quitschke WW: Two nuclear factor binding domains activate expression from the human amyloid beta-protein precursor promoter. J Biol Chem. 1994, 269: 21229-21233.PubMed
94.
Vostrov AA, Quitschke WW: The zinc finger protein CTCF binds to the APBbeta domain of the amyloid beta-protein precursor promoter. Evidence for a role in transcriptional activation. J Biol Chem. 1997, 272: 33353-33359. 10.1074/jbc.272.52.33353.PubMedCrossRef
95.
Vostrov AA, Quitschke WW, Vidal F, Schwarzman AL, Goldgaber D: USF binds to the APB alpha sequence in the promoter of the amyloid beta-protein precursor gene. Nucleic Acids Res. 1995, 23: 2734-2741. 10.1093/nar/23.14.2734.PubMedCentralPubMedCrossRef
96.
Pollwein P: Overlapping binding sites of two different transcription factors in the promoter of the human gene for the Alzheimer amyloid precursor protein. Biochem Biophys Res Commun. 1993, 190: 637-647. 10.1006/bbrc.1993.1096.PubMedCrossRef
97.
Dewji NN, Do C: Heat shock factor-1 mediates the transcriptional activation of Alzheimer's beta-amyloid precursor protein gene in response to stress. Brain Res Mol Brain Res. 1996, 35: 325-328. 10.1016/0169-328X(95)00214-D.PubMedCrossRef
98.
Grilli M, Goffi F, Memo M, Spano P: Interleukin-1beta and glutamate activate the NF-kappaB/Rel binding site from the regulatory region of the amyloid precursor protein gene in primary neuronal cultures. J Biol Chem. 1996, 271: 15002-15007. 10.1074/jbc.271.25.15002.PubMedCrossRef
99.
Grilli M, Ribola M, Alberici A, Valerio A, Memo M, Spano P: Identification and characterization of a kappa B/Rel binding site in the regulatory region of the amyloid precursor protein gene. J Biol Chem. 1995, 270: 26774-26777. 10.1074/jbc.270.45.26774.PubMedCrossRef
100.
Wang PL, Niidome T, Akaike A, Kihara T, Sugimoto H: Rac1 inhibition negatively regulates transcriptional activity of the amyloid precursor protein gene. J Neurosci Res. 2009, 87: 2105-2114. 10.1002/jnr.22039.PubMedCrossRef
101.
Ge YW, Ghosh C, Song W, Maloney B, Lahiri DK: Mechanism of promoter activity of the beta-amyloid precursor protein gene in different cell lines: identification of a specific 30 bp fragment in the proximal promoter region. J Neurochem. 2004, 90: 1432-1444. 10.1111/j.1471-4159.2004.02608.x.PubMedCrossRef
102.
Bellingham SA, Lahiri DK, Maloney B, La Fontaine S, Multhaup G, Camakaris J: Copper depletion down-regulates expression of the Alzheimer's disease amyloid-beta precursor protein gene. J Biol Chem. 2004, 279: 20378-20386. 10.1074/jbc.M400805200.PubMedCrossRef
103.
Lv H, Jia L, Jia J: Promoter polymorphisms which modulate APP expression may increase susceptibility to Alzheimer's disease. Neurobiol Aging. 2008, 29: 194-202. 10.1016/j.neurobiolaging.2006.10.001.PubMedCrossRef
104.
Tomita T: Secretase inhibitors and modulators for Alzheimer's disease treatment. Expert Rev Neurother. 2009, 9: 661-679. 10.1586/ern.09.24.PubMedCrossRef
105.
Edbauer D, Winkler E, Regula JT, Pesold B, Steiner H, Haass C: Reconstitution of gamma-secretase activity. Nat Cell Biol. 2003, 5: 486-488. 10.1038/ncb960.PubMedCrossRef
106.
De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, Von Figura K, Van Leuven F: Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature. 1998, 391: 387-390. 10.1038/34910.PubMedCrossRef
107.
Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, et al: Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature. 1995, 375: 754-760. 10.1038/375754a0.PubMedCrossRef
108.
Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, Yu CE, Jondro PD, Schmidt SD, Wang K, et al: Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science. 1995, 269: 973-977. 10.1126/science.7638622.PubMedCrossRef
109.
Uemura K, Farner KC, Nasser-Ghodsi N, Jones P, Berezovska O: Reciprocal relationship between APP positioning relative to the membrane and PS1 conformation. Mol Neurodegener. 2011, 6: 15-10.1186/1750-1326-6-15.PubMedCentralPubMedCrossRef
110.
Kovacs DM, Fausett HJ, Page KJ, Kim TW, Moir RD, Merriam DE, Hollister RD, Hallmark OG, Mancini R, Felsenstein KM, et al: Alzheimer-associated presenilins 1 and 2: neuronal expression in brain and localization to intracellular membranes in mammalian cells. Nat Med. 1996, 2: 224-229. 10.1038/nm0296-224.PubMedCrossRef
111.
Lee MK, Slunt HH, Martin LJ, Thinakaran G, Kim G, Gandy SE, Seeger M, Koo E, Price DL, Sisodia SS: Expression of presenilin 1 and 2 (PS1 and PS2) in human and murine tissues. J Neurosci. 1996, 16: 7513-7525.PubMed
112.
Mitsuda N, Roses AD, Vitek MP: Transcriptional regulation of the mouse presenilin-1 gene. J Biol Chem. 1997, 272: 23489-23497. 10.1074/jbc.272.38.23489.PubMedCrossRef
113.
Prihar G, Fuldner RA, Perez-Tur J, Lincoln S, Duff K, Crook R, Hardy J, Philips CA, Venter C, Talbot C, et al: Structure and alternative splicing of the presenilin-2 gene. Neuroreport. 1996, 7: 1680-1684. 10.1097/00001756-199607080-00031.PubMedCrossRef
114.
Pastorcic M, Das HK: An upstream element containing an ETS binding site is crucial for transcription of the human presenilin-1 gene. J Biol Chem. 1999, 274: 24297-24307. 10.1074/jbc.274.34.24297.PubMedCrossRef
115.
Pastorcic M, Das HK: Regulation of transcription of the human presenilin-1 gene by ets transcription factors and the p53 protooncogene. J Biol Chem. 2000, 275: 34938-34945. 10.1074/jbc.M005411200.PubMedCrossRef
116.
Pastorcic M, Das HK: Analysis of transcriptional modulation of the presenilin 1 gene promoter by ZNF237, a candidate binding partner of the Ets transcription factor ERM. Brain Res. 2007, 1128: 21-32.PubMedCentralPubMedCrossRef
117.
Pastorcic M, Das HK: The C-terminal region of CHD3/ZFH interacts with the CIDD region of the Ets transcription factor ERM and represses transcription of the human presenilin 1 gene. FEBS J. 2007, 274: 1434-1448. 10.1111/j.1742-4658.2007.05684.x.PubMedCrossRef
118.
Das HK: Transcriptional regulation of the presenilin-1 gene: implication in Alzheimer's disease. Front Biosci. 2008, 13: 822-832. 10.2741/2723.PubMedCrossRef
119.
Mitsuda N, Ohkubo N, Tamatani M, Lee YD, Taniguchi M, Namikawa K, Kiyama H, Yamaguchi A, Sato N, Sakata K, et al: Activated cAMP-response element-binding protein regulates neuronal expression of presenilin-1. J Biol Chem. 2001, 276: 9688-9698. 10.1074/jbc.M006153200.PubMedCrossRef
120.
Theuns J, Remacle J, Killick R, Corsmit E, Vennekens K, Huylebroeck D, Cruts M, Van Broeckhoven C: Alzheimer-associated C allele of the promoter polymorphism -22C > T causes a critical neuron-specific decrease of presenilin 1 expression. Hum Mol Genet. 2003, 12: 869-877. 10.1093/hmg/ddg098.PubMedCrossRef
121.
Lambert JC, Mann DM, Harris JM, Chartier-Harlin MC, Cumming A, Coates J, Lemmon H, StClair D, Iwatsubo T, Lendon C: The -48 C/T polymorphism in the presenilin 1 promoter is associated with an increased risk of developing Alzheimer's disease and an increased Abeta load in brain. J Med Genet. 2001, 38: 353-355. 10.1136/jmg.38.6.353.PubMedCentralPubMedCrossRef
122.
Pennypacker KR, Fuldner R, Xu R, Hernandez H, Dawbarn D, Mehta N, Perez-Tur J, Baker M, Hutton M: Cloning and characterization of the presenilin-2 gene promoter. Brain Res Mol Brain Res. 1998, 56: 57-65. 10.1016/S0169-328X(98)00028-X.PubMedCrossRef
123.
Renbaum P, Beeri R, Gabai E, Amiel M, Gal M, Ehrengruber MU, Levy-Lahad E: Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells. Gene. 2003, 318: 113-124.PubMedCrossRef
124.
Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S, et al: TREM2 variants in Alzheimer's disease. N Engl J Med. 2013, 368: 117-127. 10.1056/NEJMoa1211851.PubMedCentralPubMedCrossRef
125.
Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, et al: Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med. 2013, 368: 107-116. 10.1056/NEJMoa1211103.PubMedCentralPubMedCrossRef
126.
Klesney-Tait J, Turnbull IR, Colonna M: The TREM receptor family and signal integration. Nat Immunol. 2006, 7: 1266-1273. 10.1038/ni1411.PubMedCrossRef
127.
Takahashi K, Rochford CD, Neumann H: Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med. 2005, 201: 647-657. 10.1084/jem.20041611.PubMedCentralPubMedCrossRef
128.
Turnbull IR, Gilfillan S, Cella M, Aoshi T, Miller M, Piccio L, Hernandez M, Colonna M: Cutting edge: TREM-2 attenuates macrophage activation. J Immunol. 2006, 177: 3520-3524.PubMedCrossRef
129.
Walker DG, Link J, Lue LF, Dalsing-Hernandez JE, Boyes BE: Gene expression changes by amyloid beta peptide-stimulated human postmortem brain microglia identify activation of multiple inflammatory processes. J Leukoc Biol. 2006, 79: 596-610.PubMedCrossRef
130.
Das P, Verbeeck C, Minter L, Chakrabarty P, Felsenstein K, Kukar T, Maharvi G, Fauq A, Osborne BA, Golde TE: Transient pharmacologic lowering of Abeta production prior to deposition results in sustained reduction of amyloid plaque pathology. Mol Neurodegener. 2012, 7: 39-10.1186/1750-1326-7-39.PubMedCentralPubMedCrossRef
131.
Theuns J, Brouwers N, Engelborghs S, Sleegers K, Bogaerts V, Corsmit E, De Pooter T, van Duijn CM, De Deyn PP, Van Broeckhoven C: Promoter mutations that increase amyloid precursor-protein expression are associated with Alzheimer disease. Am J Hum Genet. 2006, 78: 936-946. 10.1086/504044.PubMedCentralPubMedCrossRef
132.
133.
Milano J, McKay J, Dagenais C, Foster-Brown L, Pognan F, Gadient R, Jacobs RT, Zacco A, Greenberg B, Ciaccio PJ: Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci. 2004, 82: 341-358. 10.1093/toxsci/kfh254.PubMedCrossRef
134.
Tamayev R, D'Adamio L: Inhibition of gamma-secretase worsens memory deficits in a genetically congruous mouse model of Danish dementia. Mol Neurodegener. 2012, 7: 19-10.1186/1750-1326-7-19.PubMedCentralPubMedCrossRef
135.
Borgegard T, Gustavsson S, Nilsson C, Parpal S, Klintenberg R, Berg AL, Rosqvist S, Serneels L, Svensson S, Olsson F, et al: Alzheimer's disease: presenilin 2-sparing gamma-secretase inhibition is a tolerable Abeta peptide-lowering strategy. J Neurosci. 2012, 32: 17297-17305. 10.1523/JNEUROSCI.1451-12.2012.PubMedCrossRef
136.
Courtney E, Kornfeld S, Janitz K, Janitz M: Transcriptome profiling in neurodegenerative disease. J Neurosci Methods. 2010, 193: 189-202. 10.1016/j.jneumeth.2010.08.018.PubMedCrossRef
Metadata
Title
Transcriptional regulation and its misregulation in Alzheimer’s disease
Authors
Xiao-Fen Chen
Yun-wu Zhang
Huaxi Xu
Guojun Bu
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Molecular Brain / Issue 1/2013
Electronic ISSN: 1756-6606
DOI
https://doi.org/10.1186/1756-6606-6-44

Other articles of this Issue 1/2013

Molecular Brain 1/2013 Go to the issue

Research

Insufficient ER-stress response causes selective mouse cerebellar granule cell degeneration resembling that seen in congenital disorders of glycosylation

Research

Weaker control of the electrical properties of cerebellar granule cells by tonically active GABAA receptors in the Ts65Dn mouse model of Down’s syndrome

Research

Molecular events in the cell types of the olfactory epithelium during adult neurogenesis

Research

Chronic fluoxetine treatment reduces parvalbumin expression and perineuronal netsin gamma-aminobutyric acidergic interneurons of the frontal cortex in adultmice

Research

NMDA receptor subunits have different roles in NMDA-induced neurotoxicity in the retina

Review

The CaMKII/NMDAR complex as a molecular memory